Guidelines for the management of myeloproliferative neoplasms

Chul Won Choi, Soo Mee Bang, Seongsoo Jang, Chul Won Jung, Hee Jin Kim, Ho Young Kim, Soo Jeong Kim, Yeo Kyeoung Kim, Jinny Park, Jong Ho Won

Research output: Contribution to journalReview articlepeer-review

18 Citations (Scopus)


Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug development. The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials. In 2011, the Korean Society of Hematology MPN Working Party devised diagnostic and therapeutic guidelines for Korean MPN patients. Subsequently, other genetic mutations have been discovered and many kinds of new drugs are now under clinical investigation. In view of recent developments, we have revised the guidelines for the diagnosis and management of MPN based on published evidence and the experiences of the expert panel. Here we describe the epidemiology, new genetic mutations, and novel therapeutic options as well as diagnostic criteria and standard treatment strategies for MPN patients in Korea.

Original languageEnglish
Pages (from-to)771-788
Number of pages18
JournalKorean Journal of Internal Medicine
Issue number6
Publication statusPublished - 2015 Nov
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 The Korean Association of Internal Medicine.


  • Essential
  • Polycythemia vera
  • Practice guideline
  • Primary myelofibrosis
  • Thrombocythemia

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Guidelines for the management of myeloproliferative neoplasms'. Together they form a unique fingerprint.

Cite this